New treatment in the horizon for patients with +BRAFV600E NSCLC waiting for a new treatment options. Phase II, Open-Label Study of #Encorafenib Plus #Binimetinib in Patients With #BRAFV600 Mutant Metastatic Non–Small-Cell Lung Cancer @RielyMD et al. N=98 💊ORR by IRR was 75%… https://t.co/nxhwhNjnff (@Latinamd)

Response rate to vemurafenib in refractory hairy cell leukemia was 96 to 100 percent; NEJM Tiacci et al, 2015 :) (@Dr_R_Kurzrock)

Today in Mexico City we launched the combination of encorafenib and binimetinib approved for adult patients with inoperable or metastatic melanoma positive at BRAF V600 mutation – @PAscierto #cancer #binimetinib #encorafenib #vemurafenib #oncodaily https://t.co/cdug6hYNaV (@oncodaily)

📣 #JCO #Editorial: Encorafenib and binimetinib: A new treatment option for BRAF V600E mutant non-small cell ➡️ https://t.co/DHACu5bmdM #LungCancer #LCSM @RielyMD (@JCO_ASCO)

Avutometinib + defactinib elicited high responses among patients w/ recurrent low grade serous ovarian cancer vs avutometinib monotherapy, supporting the use of the combination. @BanerjeeSusana @royalmarsdenNHS #ovca https://t.co/6LPaFtJlGv (@OncLive)

Check out Dr. Vivek Subbiah @VivekSubbiah @SarahCannonDocs discussing #ASCO23 Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors #LCSM #GICSM #BCSM https://t.co/RJQckViT7V (@Sameh_VuMedi)

I have #RET #nsclc. A #RET friend recently progressed on selpercatinib. Biopsy showed #BRAF V600E. Her scans now show tumor reduction & side effects (after need for initial dose reduction) are limited after 2 months on selper + encorafenib. Excited for more articles like these. (@RT_2007)

Case report of a patient with #EGFR mutant NSCLC who developed an acquired #BRAF V600E mutation on osimertinib as well as leptomeningeal disease and achieved durable control with osimertinib, dabrafenib, and trametinib. #JTOCRR @JTOonline https://t.co/TcycKvLI9x (@StephenVLiu)

🙌 Encorafenib + binimetinib demonstrates encouraging clinical benefit in patients w/ metastatic BRAFV600-Mutant non-small cell #LungCancer ➡️ https://t.co/s8YrguD6Zk #LCSM #NSCLC @RielyMD (@JCO_ASCO)

Open access article 👉🏼@ASCO educational handbook 2023 - free for all to read👉🏼Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors @JCO_ASCO @ASCOPost @OncoAlert @mgoudaMD https://t.co/qoDkRndgrG (@VivekSubbiah)

(3) Interesting data on VS-6766 from @kaushalpar - small molecule RAF/MEK clamp that inhibits BRAF, CRAF and MEK. Will toxicity separate it from SHP2 inhibitors? Will co-occurring alterations matter here? #lcsm #DAVAHawaiiLung (@TejasPatilMD)

Avutometinib + defactinib elicited high responses among patients w/ recurrent low grade serous ovarian cancer vs avutometinib monotherapy, supporting the use of the combination. @BanerjeeSusana @royalmarsdenNHS #ovca https://t.co/i0gMeFRFqm (@OncLive)

Así es. En el caso del #encorafenib para #TratamientoCancerColon con mutación BRAFV600E está financiando en 14 países europeos (🇵🇹🇫🇷🇮🇹🇧🇪...) pero NO en España 👇 https://t.co/b0715ls2dP (@hector_abella)

New @ALLIANCE_org A022004 trial led by .@RonaYaeger @MSKCancerCenter compares treatment w/encorafenib & cetuximab to usual care to reduce chance of cancer recurrence after standard surgery & chemotherapy in pts w/BRAF-mutated stage IIB-III #coloncancer: https://t.co/F1Oxrw98ah (@ALLIANCE_org)

🔥Antitumor Efficacy of Dual Blockade with Encorafenib & Cetuximab with CTx in Human BRAFV600E-mCRC @CCR_AACR https://t.co/PeIO5T2h85 👉interesting preclinical study to evaluate the best combination for targeted and chemotherapies 👇supports BREAKWATER phs-III @myESMO @OncoAlert (@ArndtVogel)

Phase II study of encorafenib + binmetinib in #BRAF V600E NSCLC available @JCO_ASCO. As 1L therapy (n=59), RR 75%, mDOR/PFS not reached, 5m DCR 64%. In later lines (n=39), RR 46%, mDOR 16.7m, mPFS 9.3m, 6m DCR 41%. https://t.co/TQUJpNUhr5 (@StephenVLiu)

Excited to announce that A022004 randomized trial of adjuvant encorafenib + cetuximab vs usual care after standard rx for BRAF V600E stage III, high risk stage II colon cancer is now activated and available to all NCTN sites. @Alliance_org @EileenMOReilly @smitha42 @SyedKazmiMD (@RonaYaeger)

📣 ASCO 2023 Colon Cancer 📣 ➡️ How does the combination of #Encorafenib and #Cetuximab differ from standard adjuvant therapy for patients with #BRAF V600E mutant #ColorectalCancer? @RonaYaeger @sloan_kettering #ASCO23 🔗 https://t.co/k0buXEgFiW (@oncologytube)

#FeatureFriday Today on #FeatureFriday, we are featuring a tweet by Dr. Arndt Vogel [@ArndtVogel] about the Plasmatic BRAF allelic fraction having a prognostic role for survival in #metastatic #ColorectalCancer treated with #BRAF inhibitors #MedTwitter (@4baseCare)

Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax https://t.co/NRyC5s2BmM #melsm #melanoma #skincancer #oncology #ASCO23 @DrBetofMDPhD @StanfordCancer @MoffittNews (@ASCOPost)

🔥Plasmatic BRAF-V600E allele fraction as a prognostic factor in #colorectalcancer treated with BRAF inhibitors @Annals_Oncology https://t.co/wmEA3KOuZp 👉high BRAF AF: >(liver) mets, worse PFS & OS 👉but may benefit from triplet💊 ✅LB to support💊guidance @myESMO @OncoAlert (@ArndtVogel)

🔥Plasmatic BRAF-V600E allele fraction as a prognostic factor in #colorectalcancer treated with BRAF inhibitors @Annals_Oncology https://t.co/wmEA3KOuZp 👉high BRAF AF: >(liver) mets, worse PFS & OS 👉but may benefit from triplet💊 ✅LB to support💊guidance @myESMO @OncoAlert (@ArndtVogel)

ICYMI: Check out this #ASCO23 simultaneous publication by @RielyMD et al on a Phase II study of encorafenib plus binimetinib in patients with metastatic BRAFV600-Mutant non small-cell #LungCancer ➡️ https://t.co/uE9hNZggul #lcsm #NSCLC (@JCO_ASCO)

Very nice efficacy of encorafenib + bimetinib in BRAF NSCLC presented by @RielyMD. This combo is currently tested in the #ENCOBRAF study sponsored by @IFCTlung, available @URCOT_lyon @CHUdeLyon. #ASCO23 Very promising combination. @OncoAlert (@s_couraud)

In a session at 4:30pm, @BanerjeeSusana & Andrew Clamp share the initial efficacy & safety results of avutometinib from a phase 2 study on #OvarianCancer: https://t.co/LMRmSOUHqI #CRUKFunded #ASCO23 @royalmarsdenNHS @ICR_London @TheChristieNHS (@CRUKresearch)

While we wait for better quality pics.. 😉 @VerastemOncolog @BanerjeeSusana @ASCO #ASCO23 RAMP201 #LGSOC #ovariancancer Phenomenal efficacy, safety data ▪︎RAF-MEK clamp avutometinib/ FAKi Defactinib. •Confirmed ORR 45% •KRASm 60% •KRAS WT 29% •(Unconfirmed ORR 52%-73%-29%) https://t.co/X6u3De05v4 (@CrozrX)

Our own @RielyMD of @MSKCancerCenter describes the results of a prospective trial of encorafenib and binimetinib for people with RAFV600E-mutant metastatic non-small cell #lungcancer. Read the paper here: https://t.co/Olgqkz01B3 #NSCLC #lcsm #ASCO23 @JCO_ASCO (@MSK_DeptOfMed)

Encorafenib + Binimetinib in BRAF V600E mutant NSCLC shows promising results. Great ORR, significant PFS and probably less toxicity than our current “SoC” with Dabra + Trame. I am such a fan of @RielyMD ;) (@MarceloCorassa)

💥 In the context of @ASCO Plenary on brain tumor #ASCO23 👉🏼sharing a major milestone in the #precisionmedicine for BRAF + glioblastoma & the first ever positive targeted therapy for brain tumors. 👉Dabrafenib + trametinib in BRAFV600E-mutant low-grade & high-grade glioma… https://t.co/ZPV7m2CX9Y (@VivekSubbiah)

Lead author @RielyMD of @MSKCancerCenter: "Overall, this shows efficacy for both first-line and second-line use of encorafenib and binimetinib for patients with BRAFV600E-mutant metastatic NSCLC." Read the paper: https://t.co/xR4UeGZhzz #ASCO23 #lcsm (@JCO_ASCO)

At @ASCO with @MehrdadZarei15 presenting our work in IDH1 inhibition as a powerful drug combination with BRAF inhibition in#Melanoma @winterlab8 @JordanMWinterMD @AlexanderLoftu9 @caseccc @UHSurgOncology @UHSurgeryRes (@LukeRothermel)

Thrilled to share our article in the ASCO educational handbook @ASCOPost @ASCO #ASCO23! Don't miss the session today 📚 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors" -->This practical guide… https://t.co/gX38X48QK5 (@VivekSubbiah)

#ASCO23 @ASCO Abs#9018 Encorafenib + binimetinib in #BRAF V600E #NSCLC #PHAROS @RielyMD @RamalingamMD @IbiayiMD @MLJohnsonMD2 @EnriquetaFelip https://t.co/SpYlYRQTL5 @OncoAlert @HemOncToday (@CharuAggarwalMD)

#ASCO23 Abs9100 #LCSM by @Joshua_Reuss 🔬 RAMP 202, a phase 2 trial, evaluated the efficacy and safety of avutometinib ± defactinib in previously-treated KRASG12V mt NSCLC. 📊 Of 35 pts with KRAS G12V, 16 received monotherapy, and 19 received combination therapy. ➡️In the… https://t.co/A3N7rq0Epc (@ADesaiMD)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma 3/3 @OncoAlert @weoncologists @Aiims1742 https://t.co/jhdFMv51fX https://t.co/goCcJcP2xH (@VivekSubbiah)

🌟 Feast your eyes on these beautiful figures we created for @VivekSubbiah for the #ASCO23 educational handbook!—FREE access! 📚 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult &Pediatric Solid Tumors"🎯🧬 #DrawImpacts (@DrawImpacts)

🚨Just days before @ASCO 👉🏼 #ASCO23 educational handbook - free open access article is out 👉🏼Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors 🎯🧬 summarizing the latest in BRAF #PrecisionMedicine… https://t.co/70SUhtdj53 (@VivekSubbiah)

🎥@rutkowskip1972 shares promising results on vemurafenib + cobimetinib for BRAF-mutated melanoma. The study shows extended OS and PFS compared to vemurafenib alone: 👉 https://t.co/168Ujoli2Z 👈 #MelSM #ESMOSarcomaandrarecancers23 @myESMO (@VJOncology)

This @SWOG study by @VanMorrisMD is still accruing. It is a Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAF Metastatic and/or Unresectable #ColorectalCancer #crcsm #SWOGonc (@ARosen380)

🎉 Hot off the press: Our figures now officially published in @ASCOPost educational handbook! Check out @VivekSubbiah & #MohamedGouda's article"Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors"🩺💥 (@DrawImpacts)

Excited to announce the publication of our article in the ASCO educational handbook @ASCOPost @ASCO #ASCO23! 📚 📢 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors" 🩺💥 This practical guide builds… https://t.co/HTPHCkQvOt (@VivekSubbiah)

NICE approve 1L Dabrafenib & Trametinib for BRAF V600E NSCLC (@tnewsomdavis)